Collaboration and License Agreements (Tables)

12 Months Ended

Mar. 31, 2022

Commitments and Contingencies Disclosure [Abstract]

Collaboration and License Agreements

The following table presents changes in the Company’s contract liabilities during the years ended March 31, 2022 and 2021 (in thousands):

	Balance at March 31, 2021		Additions		Imputed Interest		Deductions		Balance at March 31, 2022
Contract liabilities:
Deferred revenue(1)	$	497,933	$	100,000	$	—	$	(121,663)	$	476,270
Cost share advance from Pfizer(2)	$	121,862	$	—	$	2,413	$	(90,457)	$	33,818

	Balance at March 31, 2020		Additions		Imputed Interest		Deductions		Balance at March 31, 2021
Contract liabilities:
Deferred revenue(1)	$	40,000	$	513,620	$	—	$	(55,687)	$	497,933
Cost share advance from Pfizer(2)	$	—	$	146,384	$	635	$	(25,157)	$	121,862

(1) Includes $100.6 million and $375.7 million presented as current and non-current, respectively, on the consolidated balance sheet as of March 31, 2022. Includes $100.6 million and $397.4 million presented as current and non-current, respectively, on the consolidated balance sheet as of March 31, 2021.

(2) Includes $33.8 million presented as current on the consolidated balance sheet as of March 31, 2022. Includes $92.4 million and $29.4 million presented as current and non-current, respectively, on the consolidated balance sheet as of March 31, 2021.